Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02015091 · ClinicalTrials.gov registry record · Phase 1
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
A Phase 1 study of Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
- 2
- Study locations
NCT02015091: Completed Phase 1 study of Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02015091 is a Phase 1 study of Malaria that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 141 participants, below the 253-participant average among 27 other Malaria trials with a reported enrollment target (44% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02015091, a Phase 1 study of Malaria, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: \- People bitten by mosquitoes carrying weakened malaria parasites could fight off the disease if later exposed to normal malaria parasites. Scientists have discovered how to make the weakened parasites, which can be injected by the PfSPZ vaccine. Researchers want to see if people who receive the vaccine get malaria after being bitten in a controlled setting (a controlled human malaria infection, CHMI). Objective: \- To see if the PfSPZ malaria vaccine is safe and prevents malaria in a controlled setting. Eligibility: \- Healthy adults 18 45 years old. Design: * Participants will be screened with medical history, physical exam, blood and lab tests, and EKG. * Participants will be split into 8 groups, to be in the study for 3 12 months. * Participants will receive 3 5 vaccinations, injected by a needle in an arm vein or muscle. * Participants will keep a health diary and be contacted by phone. * For CHMI, a cup with mosquitoes carrying malaria is applied to participants arm for 5 minutes. Five mosquitoes at a time are used, until 5 have bitten. Some groups will be exposed to malaria more than once. * After CHMI, participants will visit the clinic very frequently (including daily visits for 12 days) for 28 days. * Blood will be drawn at most visits, from 1 to 20 tubes. Physical exam and medical history may also be repeated * Participants who develop malaria will be treated immediately at the clinic. Standard treatment takes 72 hours. Malaria symptoms may last up to 3 days.
Conditions Studied
Interventions
- BIOLOGICAL PfSPZ Vaccine
Study Locations (2)
Maryland
- University of Maryland Center for Vaccine Dev, Baltimore - Baltimore
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2013-12-12 |
| Est. Completion | 2016-09-08 |
| Phase | Phase 1 |
What the finished NCT02015091 record still lists
NCT02015091 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 253-participant average among 27 other Malaria trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 1 intervention - of which PfSPZ Vaccine is the first listed.
NCT02015091 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02015091 about?
NCT02015091 is a clinical study titled "Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults". Background: \- People bitten by mosquitoes carrying weakened malaria parasites could fight off the disease if later exposed to normal malaria parasites. Scientists have discovered how to make the weakened parasites, which can be injected by the PfSPZ vaccine. Researchers want to see if people who r...
What is the current status of trial NCT02015091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2013-12-12. Estimated completion is 2016-09-08.
What conditions does trial NCT02015091 study?
This clinical trial studies the following conditions: Malaria.
What interventions are being tested in trial NCT02015091?
The interventions under investigation include: PfSPZ Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02015091?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02015091 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02015091's enrollment target sits among peer trials
141 10th of 27 higher than 18 of 27 other Malaria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral E1018 in Healthy Adult Participants
RECRUITING · Phase 1
-
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
RECRUITING · Phase 1
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
ACTIVE NOT RECRUITING · Phase 1
-
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Evaluate CIS43LS in Healthy Adults
COMPLETED · Phase 1
-
Blood-Stage Plasmodium Vivax Cell Bank
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI